Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kadcyla
Pharma
Overall survival data blur Seagen's Tukysa-ADC path
Unlike the positive tumor progression signal, the Tukysa-Kadcyla regimen showed an increased risk of death at an interim analysis.
Angus Liu
Dec 6, 2023 8:15am
Seagen's breast cancer drug Tukysa boosts Roche's ADC
Aug 17, 2023 10:18am
Daiichi Sankyo dials up Enhertu projection
Oct 31, 2022 12:17pm
AZ, Daiichi's Enhertu, after 2 recent nods, notches trial win
Aug 15, 2022 11:45am
AZ, Daiichi's Enhertu leaps into 2L breast cancer
May 5, 2022 7:55am
Seagen undaunted by AstraZeneca-Daiichi's Enhertu
Oct 29, 2021 3:32pm
